Streetbeat News

Regulatory

TAK

Takeda shares are trading higher following the European Commission's approval of Adzynma for treating ADAMTS13 deficiency in both children and adults with congenital thrombotic thrombocytopenic purpura.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 1:00 pm

CCM

Concord Medical Services has regained compliance with the NYSE's minimum share price requirement, no longer being below the $1.00 average share price criterion.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:36 pm

DZSI

DZS shares are trading lower after the company announced it received a delisting notice from the Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:32 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of dosing in the pharmacokinetics study of AD04 for Alcohol Use Disorder. The study's topline results are expected in Q4 2024, marking a significant milestone towards initiating Phase 3 clinical trials.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 12:30 pm

PETQ

Trading halt status for PETQ was updated at 8:25:00 AM ET. The article provides information on the news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:25 pm

ADTX

Aditxt's subsidiary, Pearsanta, has submitted a proposal for a Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs of the Department of Defense.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:17 pm

MDT

Medtronic has received FDA approval for its new Simplera product, which is expected to enhance its market position in the medical device industry.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:06 pm

CTLT

NVO

Novo Nordisk's CFO announced that the company is in active discussions with antitrust regulators regarding its deal with Catalent. Despite these discussions, Novo Nordisk still expects the deal to close by the end of the year.

Portfolio Pulse from charles@benzinga.com

August 07, 2024 | 11:41 am

SPY

The EPA is investigating renewable fuel producers for allegedly using fraudulent feedstocks in biodiesel production to secure government subsidies. This could impact companies involved in the biofuel sector.

Portfolio Pulse from charles@benzinga.com

August 07, 2024 | 11:37 am

NGNE

Neurogene's NGN-401 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of Rett Syndrome. This designation is expected to expedite the development and review process of NGN-401, potentially bringing a new treatment option to market faster.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:36 am